HanchorBio (漢康生技), a trailblazer in next-generation personalized biotherapeutics, announced a successful funding round, raising $35,000,000 to accelerate the development of innovative immunotherapies. With its headquarters spanning San Francisco, Taipei, and Shanghai, this dynamic company is led by a team of pharmaceutical veterans known for their proven success in biologics discovery and global development. This significant investment underscores the growing confidence in HanchorBio’s groundbreaking Fc-based designer biologics (FBDB™) platform. The proprietary FBDB™ technology is at the heart of HanchorBio's ambition to revolutionize treatment modalities for cancer and other debilitating diseases by reactivating the immune system to target malignancies and chronic conditions from multiple angles.
The fresh capital injection will enable the company to further advance its research and development efforts, refine its multi-targeting molecular configurations, and optimize manufacturing processes to overcome current clinical and regulatory challenges. With proof-of-concept data already validated in several in-vivo animal models, HanchorBio now stands well-positioned to transition these promising findings into clinical trials and, ultimately, transformative therapies for patients facing unmet medical needs. Moreover, the funding will facilitate the scaling of operations across their strategic global hubs while deepening collaborations with research institutions and industry partners. This pivotal moment marks a new chapter in HanchorBio’s journey, reinforcing its bold vision to rewrite the future of immunotherapies and deliver life-changing solutions to patients worldwide. The support from investors not only strengthens the company’s financial foundation but also accelerates its mission to unleash the full potential of the immune system in the fight against disease.
